Graham Meta-Analysis Ultimately Positive For Celebrex, Bextra
Executive Summary
FDA Office of Drug Safety Associate Director for Science & Medicine David Graham's controversial presentation of unpublished studies on the safety of COX-2 inhibitors ultimately benefited certain COX-2s and raised questions about others in the class during a joint FDA advisory committee review
You may also be interested in...
Celebrex Gets Committee Nod For Juvenile Arthritis, But Safety Registry Urged
Concerns about cardiovascular risks associated with COX-2 inhibitors continue to haunt Pfizer's Celebrex as FDA's Arthritis Advisory Committee asked for long-term safety data as a condition of celecoxib's approval for a pediatric indication
Celebrex Gets Committee Nod For Juvenile Arthritis, But Safety Registry Urged
Concerns about cardiovascular risks associated with COX-2 inhibitors continue to haunt Pfizer's Celebrex as FDA's Arthritis Advisory Committee asked for long-term safety data as a condition of celecoxib's approval for a pediatric indication
Celebrex for juvenile RA panel review
Pfizer's COX-2 inhibitor Celebrex (celecoxib) for the treatment of juvenile rheumatoid arthritis in patients two years of age and older will be discussed by FDA's Arthritis Advisory Committee Nov. 29. The committee overwhelmingly supported continued marketing of Celebrex during a much publicized 2005 joint meeting with the Drug Safety & Risk Management Advisory Committee on the COX-2 inhibitor class (1"The Pink Sheet" March 7, 2005, p. 21). The November meeting will be held at the Hilton in Gaithersburg, Md. from 8 a.m. to 5 p.m....